Zhaoke Ophthalmology's Phase 3 Trial for Macular Degeneration Drug Meets Endpoints; Shares Rise 7%

Like
Comment
Favorite

Zhaoke Ophthalmology's Phase 3 Trial for Macular Degeneration Drug Meets Endpoints; Shares Rise 7%

MT Newswires Live01-02

Zhaoke Ophthalmology's (HKG:6622) phase 3 trial of its TAB014 treatment for wet (neovascular) age-related macular degeneration met primary and key secondary endpoints, according to a Thursday filing with the Hong Kong Exchange.

The trial enrolled 488 patients across 57 centers and assessed changes from baseline in best corrected visual acuity at 52 weeks for patients treated with TAB014.

Shares jumped 7% during Thursday's trading.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

抱歉，当前请求异常(-1)

7x24

All

22:28
Trump Signs Order Imposing Sanctions on Countries Importing Venezuelan Oil -White House
22:25
Mastermyne Group - Contract Encompasses Approximately 200 Roles at Appin Mine, Others
22:25
Mastermyne Group - Executed Contract for Contract Mining Services With Gear M Illawarra Met Coal
22:20
Fortis Inc - Net Proceeds to Reduce Borrowings and for General Corporate Purposes
22:20
Fortis Inc - Prices $600 Million Offering of 4.090% Senior Unsecured Notes Due 2032

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2500991078?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-01-02 13:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2500991078","market":"hk","top_or_hot":-1,"title":"Zhaoke Ophthalmology's Phase 3 Trial for Macular Degeneration Drug Meets Endpoints; Shares Rise 7%","media":"MT Newswires Live","content":"<html><body><p> Zhaoke Ophthalmology's (HKG:6622) phase 3 trial of its TAB014 treatment for wet (neovascular) age-related macular degeneration met primary and key secondary endpoints, according to a Thursday filing with the Hong Kong Exchange.</p><p>The trial enrolled 488 patients across 57 centers and assessed changes from baseline in best corrected visual acuity at 52 weeks for patients treated with TAB014.</p><p>Shares jumped 7% during Thursday's trading.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zhaoke Ophthalmology's Phase 3 Trial for Macular Degeneration Drug Meets Endpoints; Shares Rise 7%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZhaoke Ophthalmology's Phase 3 Trial for Macular Degeneration Drug Meets Endpoints; Shares Rise 7%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-01-02 13:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Zhaoke Ophthalmology's (HKG:6622) phase 3 trial of its TAB014 treatment for wet (neovascular) age-related macular degeneration met primary and key secondary endpoints, according to a Thursday filing with the Hong Kong Exchange.</p><p>The trial enrolled 488 patients across 57 centers and assessed changes from baseline in best corrected visual acuity at 52 weeks for patients treated with TAB014.</p><p>Shares jumped 7% during Thursday's trading.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2500991078","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2500991078","pubTimestamp":1735797220,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Zhaoke Ophthalmology's  phase 3 trial of its TAB014 treatment for wet  age-related macular degeneration met primary and key secondary endpoints, according to a Thursday filing with the Hong Kong Exchange.The trial enrolled 488 patients across 57 centers and assessed changes from baseline in best corrected visual acuity at 52 weeks for patients treated with TAB014.Shares jumped 7% during Thursday's trading.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","BK1574":"生物医药B类股","BK1587":"次新股","06622":"兆科眼科-B","BK1583":"高瓴概念"},"translate_title":"兆科眼科黄斑变性药物3期试验达到终点；股价上涨7%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06622":0.9},"content_text":"Zhaoke Ophthalmology's (HKG:6622) phase 3 trial of its TAB014 treatment for wet (neovascular) age-related macular degeneration met primary and key secondary endpoints, according to a Thursday filing with the Hong Kong Exchange.The trial enrolled 488 patients across 57 centers and assessed changes from baseline in best corrected visual acuity at 52 weeks for patients treated with TAB014.Shares jumped 7% during Thursday's trading.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}